Radiographic progression in 4 trials.
| Study | Time Evaluated, Weeks | TT | Anti-TNF + MTX | p |
|---|---|---|---|---|
| SHS, mean progression in Sharp score units | ||||
| O’Dell, et al16 (RACAT) | 24 | 0.42 | 0.003 | 0.2 |
| SHS, mean | ||||
| Moreland, et al6 (TEAR) S | Baseline | 4.8 | 4.1 | 0.047* |
| 102 | 6.2 | 4.8 | ||
| SHS (mean) | ||||
| van Vollenhoven, et al18 (SWEFOT) | Baseline | 5.48 | 4.57 | 0.118 |
| 48 | 10.23 | 8.08 | ||
| 96 | 12.15 | 9.14 | ||
| Increase from baseline to 24 mos, mean | ||||
| 7.23 | 4 | 0.009 | ||
| SHS progression, median | ||||
| Heimans, et al17 (IMPROVED) | 32 | 0 | 0 | — |
↵* Combination in 2 groups of initial treatment arm and step-up (S): the etanercept-MTX group had less radiographic progression than the TT group. Conventional: 0.64 vs 1.69, p = 0.047. Significant data are in bold face. TT: triple oral combination therapy; anti-TNF: antitumor necrosis factor; MTX: methotrexate; SHS: van der Heijde-modified Sharp score.